Genoptix, Inc. announced that it has entered into a Memorandum Of Understanding (MoU) providing for the settlement of the putative class action lawsuits currently pending in the Superior Court of the State of California, San Diego County (the Court) - captioned Page v. Genoptix, Inc., case no. 37-2011-00050762-CU-BT-NC, Schwitters v. Genoptix, Inc., case no. 37-2011-00050783-CU-BT-NC and the George Leon Family Trust v. Genoptix, Inc., case no. 37-2011-00050935-CU-BT-NC (the Actions).

The MoU resolves the allegations by plaintiffs against defendants in connection with the agreement and plan of merger, dated as of January24, 2011 (the Merger Agreement), and any disclosures related to the transactions contemplated thereby, and, pending confirmatory discovery and approval of the Court, provides for a general release by the class of Genoptix shareholders of all claims against defendants and their affiliates in connection with the merger agreement and the transactions contemplated thereby.

Pursuant to the MoU, the parties to the MoU will negotiate in good faith to execute an appropriate settlement agreement, which will provide that upon approval of the settlement, the Actions will be dismissed with prejudice. Pursuant to the terms of the MoU, Genoptix will provide additional supplemental disclosures to its solicitation/recommendation statement on Schedule 14D-9 originally filed with the Securities and Exchange Commission (the SEC) on January 28, 2011 (the Schedule 14D-9).

Genoptix believes that the supplemental disclosures are not required to be disclosed under federal securities laws or under state law and are not material as a matter of law or in the context of a stockholder's decision to tender shares of Genoptix' common stock into and accept the cash tender offer by GO Merger Sub, Inc. In the event that the settlement is not approved, the defendants will continue to vigorously defend against the allegations set forth in the Actions.

Genoptix intends to file an amendment to the Schedule 14D-9 on or about February 22, 2011 (the Amendment) to include additional supplemental disclosures provided for under the MoU. A copy of the disclosures to be provided in the Amendment is included as an attachment to this press release.

Genoptix is a specialized laboratory service provider focused on delivering personalized and comprehensive diagnostic services to community-based haematologists and oncologists.